Independent and Combined Effects of Resistance Exercise Training and β-hydroxy β-methylbutyrate Plus Vitamin D
NCT ID: NCT03848741
Last Updated: 2019-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
48 participants
INTERVENTIONAL
2019-04-01
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty
NCT07275996
Precision Medicine and Physical Function
NCT05877846
The Effect of β-hydroxy-β-methylbutyrate Supplementation on Physical Capacity and Body Composition in Trained Athletes
NCT03028649
HMB and Exercise-induced Muscle Damage
NCT04549610
Effect of Creatine+HMB Supplementation in Physically Active Older Adults
NCT05951439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Group 1 will serve as a non-exercise control with placebo; Group 2 will serve as a non-exercise control with β-hydroxy β-methylbutyrate + Vitamin D; Group 3 will complete resistance exercise training with placebo; Group 4 will complete resistance exercise training with β-hydroxy β-methylbutyrate + Vitamin D
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-exercise control with placebo
Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
Non-Exercise Control
Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
Placebo
Participants will be given placebo capsules to consume for 12-weeks.
Non-exercise control with HMB+VitD
Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
Non-Exercise Control
Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
HMB+VitD
Participants will be given HMB+VitD capsules to consume for 12-weeks
Resistance exercise training with placebo
Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules \~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
Resistance Exercise Training
Participants will complete a 12-week whole-body progressive resistance exercise training program.
Placebo
Participants will be given placebo capsules to consume for 12-weeks.
Resistance exercise training with HMB+VitD
Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules \~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
Resistance Exercise Training
Participants will complete a 12-week whole-body progressive resistance exercise training program.
HMB+VitD
Participants will be given HMB+VitD capsules to consume for 12-weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Exercise Control
Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
Resistance Exercise Training
Participants will complete a 12-week whole-body progressive resistance exercise training program.
Placebo
Participants will be given placebo capsules to consume for 12-weeks.
HMB+VitD
Participants will be given HMB+VitD capsules to consume for 12-weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women with a BMI \< 35 kg/m2
* Sedentary (\< 30 minutes of structured physical activity 3 times per week)
* Weight stable for 3 months prior (+/- 5kg)
Exclusion Criteria
* Type 1 or Type 2 diabetes
* Uncontrolled hypertension
* Active cancer, cancer in remission, or having received treatment for any form of cancer in the previous 5 years
* Cardiovascular disease (e.g., peripheral artery disease and peripheral vascular disease)
* Uncontrolled thyroid function
* Chronic and/or regular consumption of medication known to influence skeletal muscle metabolism
* Use of Vitamin D (\>2000 IU) or β-hydroxy β-methylbutyrate
* Tobacco use
* Any condition that limits exercise training (e.g., chronic obstructive pulmonary disease, neuromuscular disorder, moderate or severe cognitive impairment, Alzheimer's disease, vertigo, dizziness)
* High alcohol consumption defined as more than 8 drinks per week for women
* Unwilling to undergo any study-related procedures
* Pregnancy
* Abnormal liver or kidney enzymes determined in blood chemistry panel
* Bleeding/clotting disorders or blood thinning medications (e.g., warfarin, heparin)
45 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metabolic Technologies Inc.
INDUSTRY
University of Illinois at Urbana-Champaign
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam Konopka
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Konopka, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Illinois at Urbana-Champaign
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Freer Hall
Urbana, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
093635
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.